We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation.
- Authors
Watanabe, Marika; Yakushijin, Kimikazu; Funakoshi, Yohei; Ohji, Goh; Hojo, Wataru; Sakai, Hironori; Saeki, Miki; Hirakawa, Yuri; Matsumoto, Sakuya; Sakai, Rina; Nagao, Shigeki; Kitao, Akihito; Miyata, Yoshiharu; Koyama, Taiji; Saito, Yasuyuki; Kawamoto, Shinichiro; Ito, Mitsuhiro; Murayama, Tohru; Matsuoka, Hiroshi; Minami, Hironobu
- Abstract
Patients who have undergone hematopoietic stem cell transplantation (HSCT) for hematological disease experience high mortality when infected by coronavirus disease 2019 (COVID-19). However, the safety and efficacy of the COVID-19 vaccine in HSCT patients remain to be investigated. We prospectively evaluated the safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine (Pfizer BioNTech) in 25 Japanese allogeneic HSCT patients in comparison with 19 healthy volunteers. While anti-S1 antibody titers in almost all healthy volunteers after the second dose were higher than the cut-off value reported previously, levels in HSCT patients after the second dose were diverse. Nineteen patients (76%) had seroconversion of anti-S1 IgG. The median optical density of antibody levels in HSCT patients with low IgG levels (<600 mg/dL), steroid treatment, or low lymphocytes (<1000/μL) was significantly lower than that in the other HSCT patients. There were no serious adverse events (>Grade 3) and no new development or exacerbation of graft-versus-host disease after vaccination. We concluded that the BNT162b2 mRNA vaccine is safe and effective in Japanese allogeneic HSCT patients.
- Subjects
STEM cell transplantation; JAPANESE people; COVID-19 vaccines; HEMATOPOIETIC stem cell transplantation; IMMUNE response; COVID-19; VACCINE effectiveness
- Publication
Vaccines, 2022, Vol 10, Issue 2, p158
- ISSN
2076-393X
- Publication type
Article
- DOI
10.3390/vaccines10020158